Related Experiment Video
Updated: May 11, 2026
11:43
Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging
Published on: December 30, 2016
Mechanisms, function and clinical applications of DNp73
Cuixia Di1, Lina Yang, Hong Zhang
1Department of Heavy Ion Radiation Medicine, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.
Cell Cycle (Georgetown, Tex.)
|May 28, 2013
Summary
The truncated p73 protein (DNp73) is highly expressed in cancers and linked to tumor growth. This review summarizes DNp73
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The p73 gene generates two protein isoforms: full-length transactivating (TA) p73 and N-terminally truncated DNp73.
- DNp73 lacks the transactivating domain and its cellular function is not fully understood.
- High DNp73 expression is observed in various human cancers, suggesting pro-tumor roles.
Purpose of the Study:
- To review the expression status of DNp73 in human cancers.
- To summarize recent findings on DNp73's biological functions, including roles in apoptosis, chemosensitivity, radiosensitivity, and differentiation.
- To highlight DNp73's potential as a biomarker for cancer severity and a therapeutic target.
Main Methods:
- Comprehensive literature review of studies reporting DNp73 expression in cancer.
- Analysis of research investigating DNp73's involvement in key cellular processes.
- Synthesis of current knowledge on DNp73's clinical significance.
Main Results:
- DNp73 is frequently overexpressed across diverse human cancers.
- DNp73 influences apoptosis, chemo- and radio-sensitivity, and cellular differentiation.
- Evidence suggests DNp73 contributes to pro-tumorigenic activities.
Conclusions:
- DNp73 expression levels correlate with disease severity in cancer patients.
- DNp73 represents a promising therapeutic target for novel cancer treatments.
- Further research into DNp73's mechanisms is warranted for clinical applications.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:11IP3/DAG Signaling Pathway
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...
01:23Degenerative Disc Disease ll: Pathophysiology
The symptoms of degenerative disc disease arise from a combination of mechanical compression, vascular compromise, and biochemical inflammation, which together disrupt nerve function and produce pain.Mechanical CompressionDisc degeneration reduces height and elasticity, predisposing to herniation of the nucleus pulposus, a major cause of radicular pain. Herniations may be protrusion (bulging with intact annulus), extrusion (nucleus extends beyond disc but remains connected), or sequestration...